Authors: OTSUKA, YUICHI; KONISHI, TOSHIRO1; NARA, SATOSHI1; FURUSHIMA, KAORU1; NAKAJIMA, KENTARO1; SHIMADA, HIROSHI2 Source: Journal of Gastroenterology and Hepatology, Volume 20, Number 9, September 2005 , pp. 1318-1321(4) Publisher: Blackwell Publishing A 50-year-old man was referred to our... 

—      Istituto Nazionale Tumori, Milan (S. V., E. N., A. O., G. S., A. S.); Chair of Chemotherapy, University of Milan, (P. L., G. E., F. F.) Italy Experimental studies have suggested that the pineal hormone melatonin, in addition to its documented antineoplastic action, plays a role in the... 

Although p53 mutations occur in alkylating agent-related leukemias, their frequency and spectrum in leukemias after ovarian cancer have not been addressed. The purpose of this study was to examine p53 mutations in leukemias after ovarian cancer, for which treatment with platinum analogues was widely... 

Severe, often refractory anemia is characteristic of the myelodysplastic syndrome associated with chromosome 5q31 deletion. We investigated whether lenalidomide (CC5013) could reduce the transfusion requirement and suppress the abnormal 5q31– clone in patients with this disorder. Methods One hundred... 

Numerous studies have demonstrated a significant increase in apoptosis in patients having MDS using different methodologies.7,8,9,10 The frequency and percentage of cells showing apoptosis in these patients vary depending on the methodology used and cell population analyzed. Apoptotic cell death can... 

JENKINTOWN, Pa., February 26, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Myelodysplastic Syndromes (MDS) Guidelines. The NCCN Clinical Practice Guidelines in Oncology™ are widely recognized and applied as the standard of care in oncology in the... 

Treatment of de novo myelodysplastic syndromes may include the following: —      Supportive care with transfusion therapy. —      High-dose chemotherapy with stem cell transplant using stem cells from a donor. —      Supportive care with growth factor therapy. —      Chemotherapy... 

Takahiro Nagashima1,2, Kazuo Muroi1,2, Masae Kunitama1, Tohru Izumi1, Tetsuya Ohtsuki1, Norio Komatsu1, Masashi Fukayama3 and Keiya Ozawa 1Division of Hematology, Department of Medicine, 2Division of Cell Transplantation and Transfusion and 3Department of Pathology, Jichi Medical School, Tochigi, Japan... 

The prevalence of patients with myelodysplastic syndromes (MDS) is increasing owing to an ageing population and increased awareness of these diseases. MDS represent many different conditions, not just a single disease, that are grouped together by several clinical characteristics. A striking feature... 

(MDS, formerly known as “preleukemia”) are a diverse collection of hematological conditions united by ineffective production of blood cells and varying risks of transformation to acute myelogenous leukemia. Anemia requiring chronic blood transfusion is frequently present. ==Differential Diagnosis...